Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Last updated: January 23, 2025
Sponsor: Urotronic Inc.
Overall Status: Active - Recruiting

Phase

4

Condition

Enuresis

Peyronie's Disease

Treatment

Optilume Urethral DCB

Clinical Study ID

NCT05383274
PR1275
  • Ages 22-65
  • Male

Study Summary

Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male subjects between 22 and 65 years of age

  2. Subject diagnosed with a stricture in the anterior urethra that is able to betreated with the Optilume Urethral DCB in accordance with the approved Instructionsfor Use

  3. Subject is willing to provide written informed consent and comply with studyrequired follow-up assessments

  4. Subject able to provide viable semen samples and baseline semen qualitycharacteristics are above reference values based on below criteria (average of 2samples):

  5. total sperm ≥39 million

  6. sperm concentration ≥15 million/mL

  7. total motility ≥40%

  8. progressive motility ≥32%

  9. morphology ≥4%

Exclusion

Exclusion Criteria:

  1. Subjects with a known hypersensitivity to paclitaxel or structurally relatedcompounds

  2. Subjects with a history of vasectomy or other condition that may inhibit semen/spermproduction or ejaculatory function

  3. Subjects currently taking 5-alpha reductase inhibitors, alpha-blockers, selectiveserotonin reuptake inhibitors, or hormone replacement therapy without appropriatewashout

  4. Subject is unwilling to abstain or utilize a condom for 30 days after the procedure

  5. Subject is unwilling to utilize highly effective contraception for 6 months afterthe procedure if partner is of childbearing potential

  6. History of cancer in any body system that is not considered in complete remission

Study Design

Total Participants: 34
Treatment Group(s): 1
Primary Treatment: Optilume Urethral DCB
Phase: 4
Study Start date:
February 14, 2022
Estimated Completion Date:
December 30, 2026

Study Description

Male subject diagnosed with a stricture in the anterior urethra that can be treated with the Optilume Urethral DCB. Thirty-Four (34) subjects will be enrolled at up to ten (10) sites in the United States. Clinical follow-up will be conducted at 30 days, 3 months, 6 months, and 12 months post-treatment evaluating Lower Urinary Tract Symptoms (LUTS), sexual function, and voiding function. Semen quality parameters will be assessed at Baseline, 3 months, and 6 months post-treatment. Subjects with an abnormal semen quality result at 6 months will have an additional assessment at 12 months post-treatment and periodically thereafter until results return to normal.

Connect with a study center

  • Arkansas Urology

    Little Rock, Arkansas 72211
    United States

    Active - Recruiting

  • Orlando Health

    Orlando, Florida 32806
    United States

    Active - Recruiting

  • Florida Urology

    Tampa, Florida 33615
    United States

    Active - Recruiting

  • Regional Urology

    Shreveport, Louisiana 71106
    United States

    Active - Recruiting

  • Chesapeake

    Hanover, Maryland 21076
    United States

    Completed

  • Freedman Urology

    Las Vegas, Nevada 89144
    United States

    Active - Recruiting

  • New Jersey Urolgy

    Millburn, New Jersey 07041
    United States

    Site Not Available

  • Western New York

    Cheektowaga, New York 14225
    United States

    Active - Recruiting

  • Urology Clinics of North Texas

    Dallas, Texas 75231
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.